Published in Infect Immun on March 01, 1977
Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect Immun (1978) 3.23
The key role of peptidoglycan in the opsonization of Staphylococcus aureus. J Clin Invest (1978) 2.83
H2O2 release from human granulocytes during phagocytosis. Relationship to superoxide anion formation and cellular catabolism of H2O2: studies with normal and cytochalasin B-treated cells. J Clin Invest (1977) 2.71
Regulation of protein A synthesis by the sar and agr loci of Staphylococcus aureus. Infect Immun (1997) 2.30
Virulence of Staphylococcus aureus mutants altered in type 5 capsule production. Infect Immun (1991) 2.29
Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun (1993) 2.23
Antiopsonic activity of fibrinogen bound to M protein on the surface of group A streptococci. J Clin Invest (1982) 2.19
Activation of complement by cell surface components of Staphylococcus aureus. Infect Immun (1978) 2.03
Human fibronectin binding to staphylococcal surface protein and its relative inefficiency in promoting phagocytosis by human polymorphonuclear leukocytes, monocytes, and alveolar macrophages. Infect Immun (1981) 1.97
Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med (2010) 1.77
Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol (2011) 1.54
Immunoglobulin-binding activity among pathogenic and carrier isolates of Haemophilus somnus. Infect Immun (1989) 1.52
Insertional inactivation of a chromosomal locus that modulates expression of potential virulence determinants in Staphylococcus aureus. J Bacteriol (1995) 1.47
Staphylococcus aureus Protein A Mediates Interspecies Interactions at the Cell Surface of Pseudomonas aeruginosa. MBio (2016) 1.42
The role of Staphylococcus aureus cell-wall peptidoglycan, teichoic acid and protein A in the processes of complement activation and opsonization. Immunology (1979) 1.26
Modulation of neutrophil chemokine receptors by Staphylococcus aureus supernate. Infect Immun (2000) 1.21
A plasmid-encoded outer membrane protein, TraT, enhances resistance of Escherichia coli to phagocytosis. Infect Immun (1984) 1.15
Protective efficacy of protein A-specific antibody against bacteremic infection due to Staphylococcus aureus in an infant rat model. Infect Immun (1989) 1.14
Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother (2012) 1.08
Virulence and immunity of Staphylococcus aureus BB and certain deficient mutants. Infect Immun (1978) 1.08
Pulmonary persistence of Haemophilus somnus in the presence of specific antibody. J Clin Microbiol (1989) 1.03
An antidote for Staphylococcus aureus pneumonia? J Exp Med (2008) 1.03
Flow cytometric assay for quantifying opsonophagocytosis and killing of Staphylococcus aureus by peripheral blood leukocytes. J Clin Microbiol (1992) 1.00
Opsonic activity of normal human cerebrospinal fluid for selected bacterial species. Infect Immun (1979) 0.97
The Staphylococcus aureus GGDEF domain-containing protein, GdpS, influences protein A gene expression in a cyclic diguanylic acid-independent manner. Infect Immun (2009) 0.96
Release of protein A from the cell wall of Staphylococcus aureus. Proc Natl Acad Sci U S A (2014) 0.96
Neutrophil-Mediated Phagocytosis of Staphylococcus aureus. Front Immunol (2014) 0.93
Protein A effect on alternative pathway complement activation and opsonization of Staphylococcus aureus. Infect Immun (1981) 0.93
Staphylococcus aureus protein A promotes immune suppression. MBio (2013) 0.91
Demonstration of human immunoglobulin G Fc-binding activity in oral bacteria. Clin Diagn Lab Immunol (1994) 0.90
Transcriptional profiling of XdrA, a new regulator of spa transcription in Staphylococcus aureus. J Bacteriol (2010) 0.87
Antibody responses to protein A in patients with Staphylococcus aureus bacteremia and endocarditis. J Clin Microbiol (1990) 0.86
Lung clearance of Staphylococcus aureus strains with differing protein A content: protein A effect on in vivo clearance. Infect Immun (1978) 0.86
Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial. Hum Vaccin Immunother (2015) 0.85
Staphylococcus aureus isolates from patients with Kawasaki disease express high levels of protein A. Infect Immun (1999) 0.84
Quorum-sensing regulation in staphylococci-an overview. Front Microbiol (2015) 0.81
Reduced opsonisation of protein A containing Staphylococcus aureus in sera with cryoglobulins from patients with active systemic lupus erythematosus. Ann Rheum Dis (1985) 0.81
Effect of immunoglobulin G on the responsiveness of human neutrophils to soluble staphylococcal protein A-induced neutrophil migration inhibition factor from T-lymphocytes. Infect Immun (1980) 0.79
Evasion of Neutrophil Killing by Staphylococcus aureus. Pathogens (2016) 0.77
Staphylococcus aureus Shifts toward Commensalism in Response to Corynebacterium Species. Front Microbiol (2016) 0.77
Protein A is released into the Staphylococcus aureus culture supernatant with an unprocessed sorting signal. Infect Immun (2015) 0.77
Comparison of antisera in the fluorescent antibody test for detection of Bacteroides spp in clinical specimens. J Clin Pathol (1982) 0.75
Staphylococcal Protein A Promotes Colonization and Immune Evasion of the Epidemic Healthcare-Associated MRSA ST239. Front Microbiol (2016) 0.75
Complement activation in Staphylococcus aureus bacteraemia. Clin Exp Immunol (1980) 0.75
Staphylococcus aureus Protein A Disrupts Immunity Mediated by Long-Lived Plasma Cells. J Immunol (2016) 0.75
Cigarette Smoke Extract-Exposed Methicillin-Resistant Staphylococcus aureus Regulates Leukocyte Function for Pulmonary Persistence. Am J Respir Cell Mol Biol (2016) 0.75
"Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin. J Immunol (1966) 9.65
Significance of protein a production by staphylococci. Infect Immun (1970) 3.60
Antiphagocytic effects of staphylococcal protein A. J Immunol (1969) 2.59
Protein A isolated from Staphylococcus aureus after digestion with lysostaphin. Eur J Biochem (1972) 2.53
Sensitized sheep red cells as a reactant for Staphylococcus aureus protein A. Methodology and epidemiology with special reference to weakly reacting methicillin-resistant strains. Acta Pathol Microbiol Scand B Microbiol Immunol (1973) 2.49
Protein A mutants of Staphylococcus aureus. J Bacteriol (1971) 2.32
Protein A from Staphylococcus aureus. IX. Complement-fixing activity of protein A-IgG complexes. J Immunol (1969) 2.28
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
Protein A from Staphylococcus aureus. 8. Production of protein A by bacterial and L-forms of S. aureus. Acta Pathol Microbiol Scand (1969) 1.86
Effects of staphylococcal protein A on heat labile opsonins. J Immunol (1974) 1.73
Protein A from Staphylococcus aureus: the biological significance of its reaction with IgG. Ann N Y Acad Sci (1974) 1.62
Variation in staphylococcal protein A reactivity with gamma G-globulins of different species. Acta Pathol Microbiol Scand B Microbiol Immunol (1970) 1.26
Laboratory evaluation of a rapid, automatic susceptibility testing system: report of a collaborative study. Antimicrob Agents Chemother (1975) 17.12
Cephalosporinase and penicillinase activities of a beta-lactamase from Pseudomonas pyocyanea. Biochem J (1965) 12.54
In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood. J Clin Invest (1967) 10.26
A new type of penicillin resistance of Staphylococcus aureus. Lancet (1977) 9.15
Rapid microassay of gentamicin, kanamycin, neomycin, streptomycin, and vancomycin in serum or plasma. J Lab Clin Med (1971) 8.13
Chemotaxis under agarose: a new and simple method for measuring chemotaxis and spontaneous migration of human polymorphonuclear leukocytes and monocytes. J Immunol (1975) 8.06
Effect of inoculum and of beta-lactamase on the anti-staphylococcal activity of thirteen penicillins and cephalosporins. Antimicrob Agents Chemother (1975) 6.82
Molecular typing of methicillin-resistant Staphylococcus aureus on the basis of protein A gene polymorphism. Eur J Clin Microbiol Infect Dis (1996) 4.87
Evaluation of the Bauer-Kirby-Sherris-Turck single-disc diffusion method of antibiotic susceptibility testing. Antimicrob Agents Chemother (Bethesda) (1969) 4.12
Fatal granulomatous disease of childhood. An inborn abnormality of phagocytic function. Lancet (1966) 3.97
Kinetics of staphylococcal opsonization, attachment, ingestion and killing by human polymorphonuclear leukocytes: a quantitative assay using [3H]thymidine labeled bacteria. J Immunol Methods (1977) 3.89
Suppression of intrinsic resistance to methicillin and other penicillins in Staphylococcus aureus. Antimicrob Agents Chemother (1972) 3.88
Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis (2004) 3.69
Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics. Antimicrob Agents Chemother (1976) 3.59
The magnetic immuno polymerase chain reaction assay for direct detection of salmonellae in fecal samples. J Clin Microbiol (1992) 3.56
Chemical and physical factors influencing methicillin resistance of Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob Chemother (1977) 3.56
Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine (Baltimore) (1980) 3.42
Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect Immun (1978) 3.23
Class I integrons in Gram-negative isolates from different European hospitals and association with decreased susceptibility to multiple antibiotic compounds. J Antimicrob Chemother (1998) 3.21
Opsonic, agglutinating, and complement-fixing antibodies in patients with subacute bacterial endocarditis. J Lab Clin Med (1968) 3.20
Fungal septicemia in patients receiving parenteral hyperalimentation. N Engl J Med (1971) 3.14
Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA (1978) 3.13
Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev (1995) 3.12
Protection of phagocytized bacteria from the killing action of antibiotics. Nature (1966) 3.12
International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis (1999) 3.11
Cytochalasin B. 3. Inhibition of human polymorphonuclear leukocyte phagocytosis. Proc Soc Exp Biol Med (1971) 3.11
Kinetics of phagocytosis and bacterial killing by human polymorphonuclear leukocytes and monocytes. J Infect Dis (1977) 3.09
Susceptibility of Nocardia asteroides to 45 antimicrobial agents in vitro. Antimicrob Agents Chemother (1973) 3.05
The problems of drug-resistant pathogenic bacteria. Factors influencing methicillin resistance in staphylococci. Ann N Y Acad Sci (1971) 2.96
Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol (1992) 2.92
Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis (2000) 2.87
The key role of peptidoglycan in the opsonization of Staphylococcus aureus. J Clin Invest (1978) 2.83
Interference with granulocyte function by Staphylococcus epidermidis slime. Infect Immun (1986) 2.80
Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli. Appl Microbiol (1970) 2.75
Rapid microassay for circulating nephrotoxic antibiotics. Antimicrob Agents Chemother (Bethesda) (1970) 2.73
Opsonic requirements for staphylococcal phagocytosis. Heterogeneity among strains. Immunology (1977) 2.73
Discrimination of epidemic and nonepidemic methicillin-resistant Staphylococcus aureus strains on the basis of protein A gene polymorphism. J Clin Microbiol (1994) 2.72
Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol (2001) 2.62
Antiphagocytic effects of staphylococcal protein A. J Immunol (1969) 2.59
Synergy of antibacterial substances by apparently known mechanisms. Antimicrob Agents Chemother (Bethesda) (1967) 2.56
Enhancing effect on alkalinization of the medium on the activity of erythromycin against gram-negative bacteria. Appl Microbiol (1968) 2.55
Synergistic combinations of penicillins in the treatment of bacteriuria. N Engl J Med (1967) 2.53
The cellular immune defect in chronic mucocutaneous candidiasis. Lancet (1969) 2.53
A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (1999) 2.53
Bacterial adherence to fibronectin and endothelial cells: a possible mechanism for bacterial tissue tropism. J Lab Clin Med (1984) 2.52
Cyclic GMP and cell movement. Nature (1973) 2.46
Excretion of erythromycin and its enhanced activity in urine against gram-negative bacilli with alkalinization. J Lab Clin Med (1968) 2.45
In vitro activity of cephalosporins against methicillin-resistant, coagulase-negative staphylococci. J Infect Dis (1978) 2.39
Typing of methicillin-resistant Staphylococcus aureus isolates from Düsseldorf by six genotypic methods. J Med Microbiol (1998) 2.39
Phylogenetic diversity of Klebsiella pneumoniae and Klebsiella oxytoca clinical isolates revealed by randomly amplified polymorphic DNA, gyrA and parC genes sequencing and automated ribotyping. Int J Syst Evol Microbiol (2001) 2.38
Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis (1990) 2.36
Influence of the alternate complement pathway in opsonization of several bacterial species. Infect Immun (1974) 2.34
Studies of polymorphonuclear leukocytes from patients with chronic granulomatous disease of childhood: bactericidal capacity for streptococci. Pediatrics (1968) 2.31
Temporal trends in the population structure of Bordetella pertussis during 1949-1996 in a highly vaccinated population. J Infect Dis (1999) 2.25
Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun (1993) 2.23
Quantitation of staphylococcal protein A: Determination of equilibrium constant and number of protein A residues on bacteria. J Immunol (1970) 2.19
Chronic mucocutaneous candidiasis, deficiency of delayed hypersensitivity, and selective local antibody defect. Lancet (1967) 2.19
Cryptic peptidoglycan and the antiphagocytic effect of the Staphylococcus aureus capsule: model for the antiphagocytic effect of bacterial cell surface polymers. Infect Immun (1979) 2.17
Specific information concerning taxonomy, pathogenicity and methicillin resistance of staphylococci obtained by a multiplex PCR. J Med Microbiol (1997) 2.16
In-vivo transfer of mecA DNA to Staphylococcus aureus [corrected]. Lancet (2001) 2.14
Opsonic activity of agammaglobulinemic human sera. J Immunol (1971) 2.13
Capsular K1 polysaccharide of Escherichia coli: relationship to virulence in newborn rats and resistance to phagocytosis. Infect Immun (1979) 2.08
Opsonic activity in human serum chelated with ethylene glycoltetra-acetic acid. Immunology (1974) 2.08
Extracellular matrix proteins (fibronectin, laminin, and type IV collagen) bind and aggregate bacteria. Am J Pathol (1985) 2.08
Thiol-group binding of zinc to a beta-lactamase of Bacillus cereus: differential effects on enzyme activity with penicillin and cephalosporins as substrates. J Bacteriol (1968) 2.08
Localization of the third component of complement on the cell wall of encapsulated Staphylococcus aureus M: implications for the mechanism of resistance to phagocytosis. Infect Immun (1979) 2.07
Effect of tetracycline on the phagocytic function of human leukocytes. J Infect Dis (1974) 2.06
Mechanisms of resistance to beta-lactam antibiotics in strains of Staphylococcus aureus. Ann Intern Med (1982) 2.05
Cytochalasin B. IV. Inhibition and stimulation of chemotaxis of rabbit and human polymorphonuclear leukocytes. J Immunol (1972) 2.04
Activation of complement by cell surface components of Staphylococcus aureus. Infect Immun (1978) 2.03
Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement. J Immunol (1982) 2.02
Chemiluminescence response of phagocytizing human monocytes. Infect Immun (1976) 2.01
Rheumatoid factors in subacute bacterial endocarditis--bacterium, duration of disease or genetic predisposition? Ann Intern Med (1968) 2.00
DNA fingerprinting of Streptococcus zooepidemicus (Lancefield group C) as an aid to epidemiological study. J Infect Dis (1987) 1.99
Raised serum-IgE levels and defective neutrophil chemotaxis in three children with eczema and recurrent bacterial infections. Lancet (1974) 1.98
Inhibition of alternative complement pathway opsonization by group A streptococcal M protein. J Infect Dis (1979) 1.97
Human fibronectin binding to staphylococcal surface protein and its relative inefficiency in promoting phagocytosis by human polymorphonuclear leukocytes, monocytes, and alveolar macrophages. Infect Immun (1981) 1.97
Widespread occurrence of integrons causing multiple antibiotic resistance in bacteria. Lancet (1997) 1.96
A case-control study to assess possible triggers and cofactors in chronic fatigue syndrome. Am J Med (1996) 1.96
Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies. Clin Diagn Lab Immunol (1998) 1.93
Characterization and description of "Campylobacter upsaliensis" isolated from human feces. J Clin Microbiol (1990) 1.93
Human serum interactions with Candida albicans. J Immunol (1968) 1.93
Rapid microassays for clindamycin and gentamicin when present together and the effect of pH and of each on the antibacterial activity of the other. Antimicrob Agents Chemother (1974) 1.92
Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII, and XXV. Infect Immun (1977) 1.92